MX2023003406A - Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2. - Google Patents

Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2.

Info

Publication number
MX2023003406A
MX2023003406A MX2023003406A MX2023003406A MX2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A
Authority
MX
Mexico
Prior art keywords
her2
solid tumors
tucatinib
combination
alterations
Prior art date
Application number
MX2023003406A
Other languages
English (en)
Inventor
Luke Walker
Anita Kulukian
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2023003406A publication Critical patent/MX2023003406A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos de tratamiento de tumores sólidos, como los tumores sólidos con alteraciones de HER2, por ejemplo, tumores sólidos en las cuales el HER2 se amplifica/sobreexpresa o muta, con una combinación de tucatinib o sal o solvato del mismo y al menos un anticuerpo anti-HER2, como el trastuzumab o trastuzumab y pertuzumab.
MX2023003406A 2020-09-28 2021-09-27 Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2. MX2023003406A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063084481P 2020-09-28 2020-09-28
US202063113245P 2020-11-13 2020-11-13
US202163222335P 2021-07-15 2021-07-15
PCT/US2021/071606 WO2022067347A1 (en) 2020-09-28 2021-09-27 Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody

Publications (1)

Publication Number Publication Date
MX2023003406A true MX2023003406A (es) 2023-03-31

Family

ID=78464001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003406A MX2023003406A (es) 2020-09-28 2021-09-27 Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2.

Country Status (10)

Country Link
US (1) US20230372342A1 (es)
EP (1) EP4217400A1 (es)
JP (1) JP2023543261A (es)
KR (1) KR20230078705A (es)
CN (1) CN116437924A (es)
AU (1) AU2021349384A1 (es)
CA (1) CA3197165A1 (es)
IL (1) IL301405A (es)
MX (1) MX2023003406A (es)
WO (1) WO2022067347A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230429A1 (en) * 2022-05-22 2023-11-30 Seagen Inc. Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5413197A (en) 1994-03-14 1995-05-09 Baer; Larry G. Parking brake valve
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
US11207324B2 (en) * 2017-04-28 2021-12-28 Seagen Inc. Treatment of HER2 positive cancers
TW202042820A (zh) * 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法

Also Published As

Publication number Publication date
KR20230078705A (ko) 2023-06-02
WO2022067347A1 (en) 2022-03-31
AU2021349384A1 (en) 2023-05-25
EP4217400A1 (en) 2023-08-02
CA3197165A1 (en) 2022-03-31
CN116437924A (zh) 2023-07-14
JP2023543261A (ja) 2023-10-13
US20230372342A1 (en) 2023-11-23
IL301405A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
JOP20180021A1 (ar) الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
MX2020012561A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MY150756A (en) Tumor theraphy with an anti-vegf antibody
EA201992143A1 (ru) Биспецифические антитела, перенаправляющие т-клетки, для лечения egfr-положительных раковых заболеваний
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2023003406A (es) Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2.
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2022007962A (es) Anticuerpo anti-lilrb1 y usos del mismo.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
AR126253A2 (es) Moléculas de unión al antígeno y métodos de uso
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
MX2022011160A (es) Metodos de tratar canceres mutantes de her2 con tucatinib.